Synaptogenix Inc (SNPX)

[Cyosol]

Could be.

Either way, I agree with your viewpoint that we'll probably (hopefully) never get above 25 million fully diluted shares.

These are the numbers I use for my current projections:

Series G (late 2018/early 2019): 2 million shares sold at $10/share, bringing in $20 million that should support the company comfortably beyond the announcement of the confirmatory trial results

Series H (late 2019/early 2020): 4 million shares sold at $20/share, bringing in $80 million that will support the company until Bryostatin starts bringing in the revenue. I expect this to be the last fundraising round.

Now I personally believe that the $20 share price after positive results are announced is a very conservative estimate, but I use that number anyways since I like to underestimate these things rather than overestimate them.

In this case we would add an additional 6 million shares. Throw in a million or two more for additional options and placement warrants, and we'll maybe add another 8 million shares in total before any significant dilution stops.

14,356,968 + 8,000,000 = 22,356,968

I then round that number up to 23 million (just to be conservative again) and there you have it.

As for the future company valuation, it's really just a matter of guessing how many billions you think the world's first AD treatment will be worth.